Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis

The Pharmacogenomics Journal volume 18, pages 721–729 (2018)Cite this article

Subjects

Abstract

Numerous studies have illustrated the relationship between SLCO1B1 T521C polymorphism and statin-induced myopathy risk; however, this association is not consistent. Three electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched from inception to October 2017 to identify potential studies. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated from different genetic models by using a random-effects model. Fourteen studies comprising 3265 myopathy patients and 7743 controls were included. The summary ORs suggested that 521CC (OR: 2.31; 95% CI: 1.15–4.63; P = 0.019), 521TC (OR: 1.34; 95% CI: 1.02–1.76; P = 0.034), and 521CC + TC (OR: 1.82; 95% CI: 1.32–2.51; P < 0.001) were associated with a greater risk of statin-induced myopathy than 521TT. The higher incidence of statin-induced myopathy was found to be significantly correlated with the C allele compared with the T allele (OR: 1.89; 95% CI: 1.36–2.62; P < 0.001). In addition, we observed that 521CC + TC was associated with an increased risk of myopathy in individuals who received simvastatin (OR: 2.35; 95% CI: 1.08–5.12; P = 0.032) or rosuvastatin (OR: 1.69; 95% CI: 1.07–2.67; P = 0.024) when compared with 521TT. The 521C allele was associated with a greater risk of cerivastatin-induced myopathy than the T allele (OR: 1.95; 95% CI: 1.47–2.57; P < 0.001). The findings of this study indicated that SLCO1B1 T521C was associated with a significantly higher risk of statin-induced myopathy, especially for simvastatin, rosuvastatin, and cerivastatin. Future studies should be conducted in subjects receiving specific types of drugs, and any potential adverse events need to be explored.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (Lond, Engl). 2005;366:1267–78.

    Article  CAS  Google Scholar 

  2. Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012;13:579–94.

    Article  CAS  Google Scholar 

  3. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–90.

    Article  CAS  Google Scholar 

  4. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–16.

    Article  Google Scholar 

  5. Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91(1b):25s–30s.

    Article  CAS  Google Scholar 

  6. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8a):52c–60c.

    Article  CAS  Google Scholar 

  7. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788–97.

    Article  CAS  Google Scholar 

  8. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157–81.

    Article  CAS  Google Scholar 

  9. Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very important pharmacogene: SLCO1B1. Pharm Genom. 2010;20:211–6.

    Article  CAS  Google Scholar 

  10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

    Article  Google Scholar 

  11. Wells G, Shea B, O’ Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Hospital Research Institute; 2009. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.html.

  12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  CAS  Google Scholar 

  13. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Medical decision making: an international journal of the Society for. Med Decis Mak. 2005;25:646–54.

    Article  CAS  Google Scholar 

  14. Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration; 2008; chap 9.

  15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  Google Scholar 

  16. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;47:15–17.

    Google Scholar 

  17. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd edn. London: BMJ Books; 2001. p. 285-312.

  18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  Google Scholar 

  19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

    Article  CAS  Google Scholar 

  20. Carr DF, O’Meara H, Jorgensen AL, Campbell J, Hobbs M, Mccann G, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 2013;94:695–701.

    Article  CAS  Google Scholar 

  21. Linde R, Peng L, Desai M, Feldman D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Derm-Endocrinol. 2010;2:77.

    Article  CAS  Google Scholar 

  22. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, Mcknight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharm & Genom. 2011;21:280.

    Article  CAS  Google Scholar 

  23. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54:1609–16.

    Article  CAS  Google Scholar 

  24. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008;359:789–99.

    Article  Google Scholar 

  25. Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012;68:273–9.

    Article  CAS  Google Scholar 

  26. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013;165:1008–14.

    Article  CAS  Google Scholar 

  27. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharm J. 2012;12:233–7.

    CAS  Google Scholar 

  28. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011;89:210–6.

    Article  CAS  Google Scholar 

  29. Ferrari M, Guasti L, Maresca A, Mirabile M, Contini S, Grandi AM, et al. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol. 2014;70:539–47.

    Article  CAS  Google Scholar 

  30. Bakar NS, Neely D, Avery P, Brown C, Daly AK, Kamali F. Genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: a case-control study. Clin Pharmacol Ther. 2018;104:178–87.

    Article  Google Scholar 

  31. Sai K, Kajinami K, Akao H, Iwadare M, Sato-Ishida R, Kawai Y, et al. A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab Pharmacokinet. 2016;31:467–70.

    Article  CAS  Google Scholar 

  32. Hubacek JA, Dlouha D, Adamkova V, Zlatohlavek L, Viklicky O, Hruba P, et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit: Int Med J Exp Clin Res. 2015;21:1454–9.

    Article  CAS  Google Scholar 

  33. Liu JE, Liu XY, Chen S, Zhang Y, Cai LY, Yang M, et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study. Eur J Clin Pharmacol. 2017;73:1409–16.

    Article  CAS  Google Scholar 

  34. Duval S, Tweedie R. A nonparametric “Trim and Fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.

    Google Scholar 

  35. Ye D, Zhu X, Wang Q, Tian X, Cheng J, Zhang E. Meta-analysis of the SLCO1B1 c.521T > C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med. 2015;35:329–35.

    Article  Google Scholar 

  36. Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine. 2015;94:e1268.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the National Key R&D Program of China (no. 2016YFC0904900), National Natural Science Foundation of China (no. 81573504 and no. 81673509), Beijing Natural Science Foundation (no. 7171012), and National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (no. 2017ZX09304028 and no. 2017ZX09101001).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Peking University First Hospital, No. 6, Dahongluochang Street, Xicheng District, 100034, Beijing, China

    Qian Xiang, Shu-qing Chen, Ling-yue Ma, Kun Hu, Zhuo Zhang, Guang-yan Mu, Qiu-fen Xie, Xiao-dan Zhang & Yi-min Cui

Authors
  1. Qian Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shu-qing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ling-yue Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guang-yan Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qiu-fen Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao-dan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yi-min Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi-min Cui.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiang, Q., Chen, Sq., Ma, Ly. et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 18, 721–729 (2018). https://doi.org/10.1038/s41397-018-0054-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-018-0054-0

This article is cited by

Search

Advanced search

Quick links